Study on the effect and mechanism of ginsenoside Rg1 on survival and differentiation of implanted BMSCs in dementia model rats
1.Department of brain center, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325027; 2.Department of neurology, Jinyun People’s Hospital, Lishui, 323000; 3.Department of hand surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325027
WU Wei1,CHEN Xiaohong2,YANG Jingquan3, et al. Study on the effect and mechanism of ginsenoside Rg1 on survival and differentiation of implanted BMSCs in dementia model rats[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(9): 637-.
Abstract：Objective: To explore the effect and mechanism of ginsenoside Rg1 on survival and differentiation of implanted BMSCs in dementia model rats. Methods: Forty five male SD rats were randomly divided into the FF transected model group (model group: ambi-hippocampal fimbria-fornix transected), the bone marrow mesenchymal stem cells (BMSCs treatment group): Two weeks after the model-made, every rat received transplantation of BMSCs (10 µL, 1×106 cells) into hippocampus on both sides by Hamilton microinjector with stereotaxis, combining group (ginsenoside Rg1 combining BMSCs treatment group) received both transplantation of BMSCs and peritoneal infusion of ginsenoside Rg1 (Two weeks after the model-made, every rat received peritoneal infusion of ginsenoside Rg1 (5 mg/kg), one day a time, until a month). Survival and migration of implanted BMSCs were observed by immunohistochemistry staining. Differentiation of BMSCs was observed using immunohistochemistry double staining. In order to explore the mechanism of ginsenoside Rg1 increased the number of implanted BMSCs, RT-PCR technique was used to detect the change of NGF mRNA expression in hippocampus. Results: Six weeks after the model-made, The number of BrdU positive cells in hippocampus of combining treatment group (34.2±5.4) was more than those of simple BMSCs treatment group (10.3±4.3), difference was significant (P<0.05). The level of NGFmRNA expression in hippocampus of combining treatment group (1.13±0.21) was higher than that of BMSCs treatment group (0.75±0.12), difference was significant. Conclusion: ginsenoside Rg1 is benefit to the survival of implanted BMSCs. Ginsenoside Rg1 may facilitate the survival of implanted BMSCs by up-regulating content of NGF mRNA in hippocampus
